Latest

At BIO International Convention 2026, Mohit Trikha, PhD, CEO of Kiva Bioscience, discussed why emerging human-based preclinical models may have their greatest impact in predicting drug toxicity and tolerability rather than replacing animal testing outright.

Speaking from the show floor at BIO 2026, Dr Anil Kane, Thermo Fisher Scientific's global head of technical and scientific affairs, details how AI partnerships are accelerating drug development decisions across the CDMO continuum.

The FDA's approval of sacituzumab govitecan-hziy for first-line metastatic triple-negative breast cancer validates the Trop-2/SN-38 hydrolyzable linker platform across four positive Phase 3 trials, with implications for ADC development strategy, pharmacogenomic labeling, and biomarker-stratified regulatory programs.

As the biologic pipeline diversifies across ADCs, bispecific antibodies, and fusion proteins, formulation science has become the critical discipline bridging molecular complexity and patient-ready therapy.

At BIO 2026, Dr Howard Berman, ReAlta Life Sciences’ CEO, explains how an astrovirus-derived anti-inflammatory peptide targets multiple pathways that drive neonatal hypoxic-ischemic encephalopathy (HIE).

AI models can deliver transformative insights into drug manufacturing, but only when fed complete, traceable, and representative datasets.

At BIO International Convention 2026, Sabeen Mekan, MD, Vice President of Clinical Development at Zymeworks and panelist for The Next Generation of ADCs: Building Kinder, Gentler Cancer Therapeutics, discusses why safety is becoming an increasingly important differentiator in antibody-drug conjugate development and how biomarker-driven patient selection may help guide future treatment decisions.

MilliporeSigma Global Head of Process Solutions Sebastián Arana outlines why manufacturing flexibility, not just capacity, is now the strategic priority for biomanufacturers at BIO 2026.

This episode explores a first-in-class antibody entering the clinic for kidney fibrosis, the world's first approved bispecific ADC, and a major acquisition that strengthens AbbVie's immunology pipeline.

Dr Wyatt McDonnell, Infinimune CEO and co-founder, posits that translatable, decision-linked single-cell data, and not data volume, are what drive effective therapeutic antibody development in this second segment of an interview at BIO 2026.

Mediar Therapeutics has dosed the first participants in a Phase 1 trial evaluating MTX-439, a first-in-class monoclonal antibody targeting SMOC2 for fibrosis associated with chronic kidney disease. The study marks the company's third anti-fibrotic program to enter clinical development and highlights growing interest in fibrosis-directed biologics.

China's National Medical Products Administration has approved izalontamab brengitecan (iza-bren) for recurrent or metastatic nasopharyngeal carcinoma, making it the first bispecific antibody-drug conjugate to receive regulatory approval anywhere in the world.

AbbVie has entered a definitive agreement to acquire Apogee Therapeutics for $10.9 billion, adding zumilokibart, a subcutaneous half-life extended IL-13 monoclonal antibody in Phase 3 development for atopic dermatitis, asthma, and eosinophilic esophagitis.